News
PHAR
10.44
-3.06%
-0.33
Canaccord Genuity Reaffirms Their Buy Rating on Pharming Group (PHAR)
TipRanks · 1d ago
Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.
Dow Jones · 2d ago
HC Wainwright & Co. Reiterates Buy on Pharming, Maintains $37 Price Target
Benzinga · 2d ago
Analysts’ Top Healthcare Picks: The Ensign Group (ENSG), Pharming Group (PHAR)
TipRanks · 2d ago
Pharming’s initial Phase 2 Leniolisib data ‘encouraging,’ says H.C. Wainwright
TipRanks · 2d ago
Pharming announces ‘positive’ Phase 2 topline data for leniolisib in PIDs
TipRanks · 2d ago
Weekly Report: what happened at PHAR last week (0914-0918)?
Weekly Report · 3d ago
U.S. 10 Year tops 5% for the first time since October of 2023
Seeking Alpha · 09/14 14:47
Analysts’ Top Healthcare Picks: Pharming Group (PHAR), Solid Biosciences (SLDB)
TipRanks · 09/14 10:40
Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.
Dow Jones · 09/14 10:40
Weekly Report: what happened at PHAR last week (0907-0911)?
Weekly Report · 09/14 10:21
Pharming Gets FDA Approval For Joenja In Children With APDS
NASDAQ · 09/11 20:54
Pharming Wins FDA Approval For Joenja In Children Ages 4 To 11 Who Weigh At Least 27kg, With New 40mg/50mg Twice-Daily Doses Expected In October
Benzinga · 09/11 18:02
Pharming wins approval of Joenja for younger age group
Seeking Alpha · 09/11 17:10
FDA approves Joenja tablets for children aged 4-11 with APDS
TipRanks · 09/11 16:15
Pharming: Faltering Rare-Disease Franchise With Two Potentially Transformative Late-Stage Assets
Seeking Alpha · 09/09 07:55
Weekly Report: what happened at PHAR last week (0831-0904)?
Weekly Report · 09/07 10:15
Weekly Report: what happened at PHAR last week (0824-0828)?
Weekly Report · 08/31 10:22
Weekly Report: what happened at PHAR last week (0817-0821)?
Weekly Report · 08/24 10:23
Weekly Report: what happened at PHAR last week (0810-0814)?
Weekly Report · 08/17 10:24
More
Webull provides a variety of real-time PHAR stock news. You can receive the latest news about Pharming Group N.V. through multiple platforms. This information may help you make smarter investment decisions.
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.